Gastrointestinal (GI) cancers and neuroendocrine neoplasms (NENs) represent a diverse and clinically challenging group of malignancies with rising global incidence especially among younger individuals. Colorectal, gastric, pancreatic, biliary tract, and hepatocellular carcinomas together account for a major proportion of cancer-related deaths worldwide. Similarly, NENs—once considered rare—are rising in incidence with heterogeneity in biology, clinical course, and response to therapy. Despite major progress in systemic treatments, surgical techniques, and molecular profiling, outcomes remain suboptimal for many patients.

In recent years, comprehensive molecular profiling has not only provided novel insights into tumor biology and resistance mechanisms but also helped uncover several actionable therapeutic targets. Parallel advances in immunotherapy, targeted therapies, and radiopharmaceuticals have reshaped the treatment landscape for select patient populations. At the same time, efforts to better understand tumor–microenvironment interactions, clonal evolution, and mechanisms of therapeutic resistance are yielding new opportunities for translational research.

This Collection aims to highlight recent advances in the biology, diagnosis, and management of GI cancers and NENs. We invite contributions spanning molecular and cellular mechanisms, biomarker discovery, innovative therapeutic strategies, clinical trial design, and translational approaches that bridge the gap from bench to bedside. Together, these works will underscore the evolving paradigms that hold promise for improving outcomes in these complex diseases.

Keywords: Gastrointestinal cancers, neuroendocrine neoplasms, biomarkers, tumor microenvironment, immunotherapy, radiopharmaceuticals, precision oncology, translational research

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, although recent years have seen remarkable progress in its clinical management. This Collection aims to deepen the evolving landscape of lung cancer through a comprehensive lens, including early diagnosis, molecular profiling (through liquid and tissue), therapeutic innovation, and simultaneous care strategies. The Collection will gather original research, reviews, short reports or letters and case studies focused on:

advances in early detection and biomarker discovery and development;

the evolution of precision oncology and molecular profiling;

updates on systemic therapies, including immunotherapy and targeted agents;

novel treatment combination strategies,

the increasing integration of simultaneous care into multidisciplinary models for improving patient outcomes.

Keywords: lung cancer; precision oncology; immunotherapy; molecular diagnostics; simultaneous care